Sökning: WFRF:(Gispert J.) >
Association of weig...
Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease
-
Grau-Rivera, O. (författare)
-
Navalpotro-Gomez, I. (författare)
-
Sanchez-Benavides, G. (författare)
-
visa fler...
-
Suarez-Calvet, M. (författare)
-
Mila-Aloma, M. (författare)
-
Arenaza-Urquijo, E. M. (författare)
-
Salvado, G. (författare)
-
Sala-Vila, A. (författare)
-
Shekari, M. (författare)
-
Gonzalez-de-Echavarri, J. M. (författare)
-
Minguillon, C. (författare)
-
Ninerola-Baizan, A. (författare)
-
Perissinotti, A. (författare)
-
Simon, M. (författare)
-
Kollmorgen, G. (författare)
-
- Zetterberg, Henrik, 1973 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Blennow, Kaj, 1958 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Gispert, J. D. (författare)
-
Molinuevo, J. L. (författare)
-
Alfa Study, Alfa Study (författare)
-
visa färre...
-
(creator_code:org_t)
- 2021-02-17
- 2021
- Engelska.
-
Ingår i: Alzheimer's Research & Therapy. - : Springer Science and Business Media LLC. - 1758-9193. ; 13:1
- Relaterad länk:
-
https://alzres.biome...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundRecognizing clinical manifestations heralding the development of Alzheimer's disease (AD)-related cognitive impairment could improve the identification of individuals at higher risk of AD who may benefit from potential prevention strategies targeting preclinical population. We aim to characterize the association of body weight change with cognitive changes and AD biomarkers in cognitively unimpaired middle-aged adults.MethodsThis prospective cohort study included data from cognitively unimpaired adults from the ALFA study (n=2743), a research platform focused on preclinical AD. Cognitive and anthropometric data were collected at baseline between April 2013 and November 2014. Between October 2016 and February 2020, 450 participants were visited in the context of the nested ALFA+ study and underwent cerebrospinal fluid (CSF) extraction and acquisition of positron emission tomography images with [F-18]flutemetamol (FTM-PET). From these, 408 (90.1%) were included in the present study. We used data from two visits (average interval 4.1years) to compute rates of change in weight and cognitive performance. We tested associations between these variables and between weight change and categorical and continuous measures of CSF and neuroimaging AD biomarkers obtained at follow-up. We classified participants with CSF data according to the AT (amyloid, tau) system and assessed between-group differences in weight change.ResultsWeight loss predicted a higher likelihood of positive FTM-PET visual read (OR 1.27, 95% CI 1.00-1.61, p=0.049), abnormal CSF p-tau levels (OR 1.50, 95% CI 1.19-1.89, p=0.001), and an A+T+ profile (OR 1.64, 95% CI 1.25-2.20, p=0.001) and was greater among participants with an A+T+ profile (p<0.01) at follow-up. Weight change was positively associated with CSF A42/40 ratio (beta =0.099, p=0.032) and negatively associated with CSF p-tau (beta=-0.141, p=0.005), t-tau (beta=-0.147 p=0.004) and neurogranin levels (beta=-0.158, p=0.002). In stratified analyses, weight loss was significantly associated with higher t-tau, p-tau, neurofilament light, and neurogranin, as well as faster cognitive decline in A+ participants only.ConclusionsWeight loss predicts AD CSF and PET biomarker results and may occur downstream to amyloid-beta accumulation in preclinical AD, paralleling cognitive decline. Accordingly, it should be considered as an indicator of increased risk of AD-related cognitive impairment.Trial registrationNCT01835717, NCT02485730, NCT02685969.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- Alzheimer's disease
- Preclinical
- Cognitively unimpaired
- Weight loss
- Biomarkers
- Risk factors
- Neurosciences & Neurology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Grau-Rivera, O.
-
Navalpotro-Gomez ...
-
Sanchez-Benavide ...
-
Suarez-Calvet, M ...
-
Mila-Aloma, M.
-
Arenaza-Urquijo, ...
-
visa fler...
-
Salvado, G.
-
Sala-Vila, A.
-
Shekari, M.
-
Gonzalez-de-Echa ...
-
Minguillon, C.
-
Ninerola-Baizan, ...
-
Perissinotti, A.
-
Simon, M.
-
Kollmorgen, G.
-
Zetterberg, Henr ...
-
Blennow, Kaj, 19 ...
-
Gispert, J. D.
-
Molinuevo, J. L.
-
Alfa Study, Alfa ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
- Artiklar i publikationen
-
Alzheimer's Rese ...
- Av lärosätet
-
Göteborgs universitet